When the Label Lies: Eight Hallucinogen Disasters and the Failure Chains Behind Them

Safety note: These are historical toxicology case studies, not dosing guidance. A seizure, collapse, severe agitation, dangerous overheating, chest pain, breathing difficulty, blue or very pale skin, extreme confusion, or inability to wake someone after a drug exposure is an emergency. Contact emergency services and a poison center rather than waiting for the experience to pass.

Executive Summary

Hallucinogen disasters are not all variations of a “bad trip.” Some begin with a false label. Others begin with delayed onset, a powder that resembles another drug, a plant whose delirium is mistaken for psychedelic insight, or a compound whose cardiac toxicity persists long after its subjective effects should have ended.

This review examines eight documented incidents:

1. Konawa, Oklahoma, 2011: liquid believed to contain 2C-E was later reported to contain Bromo-DragonFLY. Eight young adults became severely ill; two died.
2. Rural New South Wales, 2014: a 16-year-old swallowed blotter sold as LSD and developed four seizures, respiratory failure, severe acidosis, rhabdomyolysis, and kidney injury. Testing identified 25B-NBOMe.
3. San Francisco, 1967: unusually strong DOM tablets circulated as STP. Slow onset encouraged redosing and the prolonged experience sent dozens of people to clinics and hospitals.
4. San Francisco, 1972: eight adults inhaled pure LSD tartrate after mistaking the powder for cocaine. Five became comatose; complications included hyperthermia, respiratory arrest, vomiting, and bleeding abnormalities. All survived.
5. United States, 2013: an 18-year-old intoxicated with 25I-NBOMe jumped from a moving car and remained intermittently aggressive for nearly two days.
6. Australia, 2022 report: five people encountered powder sold as “powdered LSD.” It contained 25B-NBOH; one patient developed status epilepticus requiring intubation.
7. Ibogaine cardiac cases: internet-purchased or high-dose ibogaine produced profound QT prolongation, torsades de pointes, ventricular flutter, defibrillation, and rhythm instability lasting up to 12 days.
8. Datura poisonings: teenagers seeking hallucinations developed anticholinergic delirium, combativeness, incoherent speech, and loss of reality testing after swallowing hundreds of jimsonweed seeds.

The shared lesson is not that every psychoactive substance has the same risk. It is that identity, potency, time course, and toxicological profile matter more than the name, artwork, container, seller confidence, or apparent precision of the dose.

Eight Incidents at a Glance

Case One: The 2011 Oklahoma Bromo-DragonFLY Poisoning

A careful-looking method built on a false identity

According to a probable-cause affidavit, powder ordered online and labeled as 2C-E was dissolved into water. One gram was reportedly mixed into one liter, after which measured liquid portions were distributed [1].

Liquid measurement can reduce inconsistency only when the starting material is correctly identified and its concentration is known. Here, officials later reported that the material was Bromo-DragonFLY rather than 2C-E [2].

The potency mismatch was not trivial. The group appears to have planned around a milligram-scale psychedelic. Bromo-DragonFLY can be active at much smaller quantities and has been associated with delayed onset, seizures, prolonged agitation, cardiovascular stress, severe vasoconstriction, tissue injury, organ failure, and death [3, 4].

The emergency and the uncertainty

Eight young adults became severely ill near Konawa in the early hours of May 7, 2011. One died that day and another several days later. Six survived [1, 2].

The exact quantity swallowed by each person, the powder’s purity, and the uniformity of the solution were not publicly established well enough to reconstruct individual doses. The most defensible conclusion is therefore not a dramatic exact multiplier. It is simpler: the chemical identity was wrong, so every downstream dosing assumption was wrong.

Adding more water would have lowered concentration per mouthful, but it would not have reduced the total amount in a finished drink. Measurement precision cannot rescue false source information.

Case Two: 25B-NBOMe Blotter Sold as LSD

A 16-year-old camping with friends in rural New South Wales swallowed red blotter paper he believed was LSD [5]. He experienced three seizures before reaching the emergency department and a fourth after arrival.

His blood pH fell to 6.93, accompanied by severe carbon-dioxide retention—evidence of profound ventilatory failure during the crisis. Clinicians sedated, paralyzed, intubated, and mechanically ventilated him.

The injury continued after seizure control. His creatine kinase climbed to 34,778 U/L, indicating severe rhabdomyolysis, and he developed acute kidney injury. Specialized analysis identified 25B-NBOMe. He recovered and left the hospital after five days [5].

Blotter is a delivery material, not a chemical identity test. This case was dangerous precisely because the square looked ordinary. Reviews of confirmed NBOMe poisonings describe seizures, hyperthermia, hypertension, agitation, muscle breakdown, kidney injury, coma, self-injury, and death [6].

Case Three: The 1967 DOM/STP Outbreak

In June 1967, DOM tablets circulated in San Francisco under the name STP, often expanded as “Serenity, Tranquility and Peace.” The compound was unfamiliar to most users and clinicians, and historical accounts indicate that tablets around 10 milligrams—and some reportedly stronger—entered circulation [7].

DOM can build slowly and last far longer than many users expected. People accustomed to a faster onset sometimes interpreted the quiet first hours as evidence of weak material and took another tablet. When the first dose continued rising and the second followed behind it, the experience could become overwhelmingly intense and prolonged.

Dozens reportedly sought help from the Haight-Ashbury Free Medical Clinic and San Francisco General Hospital. Some required sedation or hospitalization for severe psychiatric disturbance. No confirmed deaths were directly attributed to the outbreak, and later retellings often inflated the scale, but the event remains a classic information failure: strong tablets, delayed onset, long duration, mass distribution, and doctors initially uncertain what “STP” meant [7].

The outbreak also helped push crisis care toward quieter surroundings, reassurance, observation, and less reflexively coercive treatment—an important improvement born from an otherwise chaotic episode.

Case Four: Eight People Mistake Pure LSD Powder for Cocaine

On July 29, 1972, four women and four men arrived at San Francisco General Hospital after inhaling a white powder they believed was cocaine. It was pure LSD tartrate [8].

This was the inverse of the familiar “fake acid” story. The chemical really was LSD, but the group handled it as though it were a substance normally consumed in visible powder-sized amounts.

Within minutes, vomiting, collapse, extreme agitation, and altered consciousness appeared. Five patients became comatose. Reported complications included hyperthermia, respiratory arrest, and mild generalized bleeding. Laboratory testing showed platelet dysfunction in all eight, and LSD was measured in serum and stomach contents at concentrations rarely encountered clinically [8].

No antidote could switch the exposure off. Treatment consisted of respiratory and cardiovascular support, cooling, monitoring, and management of complications. Remarkably, all eight survived.

The case should not be used to claim that massive LSD exposure is harmless. It documented life-threatening systemic toxicity. Its lesson is that a powder’s appearance can import the dosage assumptions of an entirely different drug.

Case Five: The 25I-NBOMe Jump from a Moving Car

An 18-year-old arrived at an emergency department with severe agitation and hallucinations after jumping from a moving car. His heart rate was approximately 150 to 160 beats per minute, and his blood pressure was markedly elevated [9].

He required physical restraints and intravenous lorazepam. His vital signs gradually normalized, but episodes of aggression continued during a recovery lasting roughly 48 hours. Toxicological analysis quantified 25I-NBOMe in his serum [9].

This case illustrates a risk that laboratory values alone do not capture: behavioral toxicity. A drug can transform perception and threat assessment so radically that an immediately dangerous action feels necessary or sensible. The medical crisis may begin with trauma, exposure, wandering, drowning, or confrontation before the chemical toxicity is even recognized.

Case Six: “Powdered LSD” That Was Actually 25B-NBOH

Five patients presented after exposure to powder sold as “powdered LSD” at a party. Chemical analysis identified 25B-NBOH, a potent hallucinogenic phenethylamine related to the NBOMe family [10].

A 24-year-old who swallowed the powder developed dilated pupils, tachycardia, hypertension, and severe agitation requiring injected sedation. A 22-year-old who inhaled it developed status epilepticus—a prolonged seizure emergency—and required intubation.

Both severely affected patients developed acute kidney injury; one developed rhabdomyolysis. Three others experienced milder hallucinations. Acute toxicity resolved within approximately 12 hours [10].

The powder format matters. Ultra-potent compounds are often placed on blotter partly because a visible scoop or line can represent far too much material. Calling an unknown powder “LSD” did more than misname it; it encouraged users to borrow the handling assumptions of a different substance.

Case Seven: Ibogaine and the Heart That Would Not Reset

Ibogaine occupies a complicated cultural space: psychedelic, traditional plant alkaloid, and unapproved anti-addiction intervention. Its most alarming documented risk is not simply psychological distress but prolonged electrical instability of the heart.

In one case involving internet-purchased ibogaine, a patient’s corrected QT interval reached 647 milliseconds. He developed atrial tachycardia, ventricular tachycardia, and torsades de pointes. QT prolongation persisted for 12 days—well after parent ibogaine levels had fallen—implicating the long-lasting metabolite noribogaine [11].

A separate case involved a 61-year-old man who developed ventricular flutter at approximately 270 beats per minute and required emergency defibrillation. His QT interval took seven days to normalize [12].

This creates a uniquely deceptive timeline: the visionary or intoxicating phase may be ending while the cardiac danger remains. Unlike a brief panic reaction, the risk can persist across many sleep cycles and requires prolonged medical monitoring.

Ibogaine’s case also exposes the limits of framing psychoactive substances only by their subjective experience. A person may feel mentally clearer while their cardiac repolarization remains dangerously abnormal.

Case Eight: Datura and the Difference Between Hallucination and Delirium

Two teenagers intentionally swallowed several hundred seeds from Datura stramonium, or jimsonweed, seeking hallucinogenic effects. They arrived with visual hallucinations, profound disorientation, incomprehensible speech, dilated pupils, and severe combativeness. Both required physical restraints until sedation was achieved [13].

Datura is better described as a deliriant than a classic psychedelic. Its atropine- and scopolamine-like compounds impair the brain systems needed to distinguish internal events from external reality. A person may speak with nonexistent people, manipulate imaginary objects, wander into danger, or fight rescuers without recognizing that the experience is drug-induced.

A historical review of 29 adolescent hospitalizations following intentional jimsonweed ingestion found that every patient had hallucinations, dilated pupils, and disorientation. Five developed urinary retention severe enough to require catheterization. All recovered, but the average hospitalization lasted nearly two days [14].

Calling Datura a “natural hallucinogen” obscures the central danger. Natural origin says nothing about predictability, therapeutic margin, or the ability to retain insight.

The Shared Failure Chains

1. Appearance and format became counterfeit evidence

Blotter was assumed to mean LSD. White powder was assumed to mean cocaine. A standardized-looking tablet implied a manageable unit. A plant was assumed to offer a gentler “natural” experience.

None of those appearances established identity or safety.

2. Potency assumptions were borrowed from the wrong substance

The Oklahoma group used a plan intended for 2C-E. The 1972 group handled LSD like cocaine. The 25B-NBOH cluster handled an ultra-potent compound as a visible powder.

When two substances differ by orders of magnitude, a small identification error becomes an enormous exposure error.

3. Delayed onset encouraged accumulation

Bromo-DragonFLY and DOM can develop slowly. Lack of early effect may be misread as weak material rather than delayed pharmacokinetics. By the time the first dose declares itself, additional doses cannot be taken back.

4. The danger was sometimes behavioral rather than purely biochemical

The 25I-NBOMe patient jumped from a moving vehicle. Datura intoxication produced delirium and combativeness. A person can be medically endangered through impaired judgment even before temperature, heart rhythm, kidney function, or seizure activity becomes abnormal.

5. Toxicity outlasted the expected “trip”

Ibogaine-related QT prolongation persisted for seven to 12 days. DOM experiences lasted far longer than many users anticipated. Prolonged metabolites and receptor effects can make subjective recovery a poor guide to medical recovery.

6. Group exposure compressed the warning window

When several people consume the same material around the same time, the first severe reaction may begin too late to warn everyone else. Shared confidence amplifies rather than corrects the original mistake.

7. Emergency medicine began with incomplete information

Routine toxicology panels cannot identify every novel psychoactive substance. Clinicians often must control seizures, temperature, breathing, circulation, agitation, and trauma before confirmatory testing exists—or without ever receiving a definitive identification.

What Drug Checking and Regulation Can Change

These cases support a strong criticism of an entirely underground market. Prohibition does not eliminate demand, but it can weaken the infrastructure that normally makes a chemical product legible:

• verified identity;
• batch records and traceability;
• standardized concentration;
• contamination screening;
• enforceable labeling;
• adverse-event reporting;
• recalls and rapid public warnings;
• accountability for manufacturing or distribution failures.

Drug checking can sometimes identify unexpected compounds and narrow the information gap. A regulated framework could add manufacturing standards, age restrictions, screening, and clearer education.

But neither testing nor regulation makes every hallucinogen safe. Analytical methods have limits, mixtures can be uneven, and accurately identified substances can still cause panic, delirium, seizures, cardiovascular complications, trauma, or psychiatric destabilization. Ibogaine would still affect cardiac ion channels; Datura would still produce anticholinergic delirium; Bromo-DragonFLY would remain unusually potent and vasoconstrictive.

The realistic goal is not zero risk. It is replacing avoidable uncertainty with better information, earlier recognition, and faster intervention.

Emergency Lessons That Do Not Depend on Knowing the Drug

When chemical identity is uncertain, symptoms matter more than guessing the name.

Seek emergency help for:

• any seizure or repeated uncontrolled movement;
• collapse, loss of consciousness, or inability to wake the person;
• severe breathing difficulty;
• chest pain, fainting, or an extreme or irregular heart rate;
• dangerous overheating;
• blue, gray, unusually pale, or cold skin or extremities;
• severe confusion, delirium, violence, or behavior creating immediate danger;
• persistent vomiting with reduced consciousness;
• muscle rigidity, profound weakness, or dark urine after severe agitation or seizures.

Do not let a severely affected person drive, wander away, or remain alone. Give responders any packaging, blotter, powder, messages, product listings, or vendor information available. An honest timeline is more useful than a confident but unverified drug name.

Bottom Line

These eight incidents span different decades, countries, chemical classes, and patterns of use. Some involved substitution. Some involved delayed onset. Some involved cardiac toxicity, prolonged seizures, or delirium. One involved genuine LSD mistaken for cocaine; another involved a compound sold as “powdered LSD” that was not LSD at all.

Together, they demonstrate a durable principle:

A precise measurement—or a familiar appearance—does not establish chemical identity, potency, or safety.

The paper square, tablet, powder, plant, label, online listing, and seller’s confidence are not analytical evidence. When identity, time course, and toxicology are uncertain, behavior that feels careful can still rest on a false foundation.